ANI Pharmaceuticals Company Profile (NASDAQ:ANIP)

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings data on Thursday, August, 3rd. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.79 by $0.19. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The business's revenue for the quarter was up 43.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.11 EPS. View ANI Pharmaceuticals' Earnings History.

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for ANI Pharmaceuticals.

3 equities research analysts have issued twelve-month price targets for ANI Pharmaceuticals' stock. Their predictions range from $56.00 to $80.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $67.33 in the next twelve months. View Analyst Ratings for ANI Pharmaceuticals.

Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:

• 1. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)
• 2. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (7/5/2017)

Some companies that are related to ANI Pharmaceuticals include Medpace Holdings (MEDP), Immunomedics (IMMU), Esperion Therapeutics (ESPR), Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Spectrum Pharmaceuticals (SPPI), Momenta Pharmaceuticals (MNTA), Arena Pharmaceuticals (ARNA), Cellectis S.A. (CLLS), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Albany Molecular Research (AMRI), BeyondSpring (BYSI), Heron Therapeutics (HRTX), Crispr Theraptc (CRSP), AC Immune SA (ACIU) and Abeona Therapeutics (ABEO).

ANI Pharmaceuticals' management team includes the folowing people:

• Robert E. Brown Jr., Independent Chairman of the Board
• Arthur S. Przybyl, President, Chief Executive Officer, Director
• Stephen P. Carey, Chief Financial Officer, Vice President
• James G. Marken, Vice President - Operations
• Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
• Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
• Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing
• Fred E. Holubow, Independent Director
• Tracy L. Marshbanks Ph.D., Independent Director
• Thomas A. Penn, Independent Director

Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ANI Pharmaceuticals stock can currently be purchased for approximately $57.49.